Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is a common, progressive disorder of the airways and lung parenchyma and is the fourth leading cause of death.[@CIT0001] Clinical variables that predict mortality are important for identifying patients at highest risk and include lung function, exacerbation burden and comorbidities.[@CIT0001]--[@CIT0004] Interestingly, when comparing mortality risk based purely on lung function and the symptoms-exacerbation risk-based Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 COPD classification, lung function served as a better predictor.[@CIT0005]

It has long been debated whether forced expiratory volume in one second (FEV~1~) or forced vital capacity (FVC) is the best physiological prognostic measure and if the relationship between FEV~1~ and mortality is due to airflow limitation or low lung volumes. Analyzing the 7489 participants in the general population in the Atherosclerosis Risk in Communities study, Burney & Hooper concluded that the overall mortality was more strongly related to FVC than to FEV~1;~[@CIT0006] this was supported by a post hoc analysis of the Burden of Obstructive Lung Disease study reporting that the national COPD related mortality was more strongly associated with the prevalence of spirometric restriction than obstruction.[@CIT0007] In contrast, other analyses, such as the Normative Aging Study concluded that FEV~1~ is more strongly related to mortality than FVC in a general population.[@CIT0008]

Cardiovascular disease (CVD) frequently accompanies COPD.[@CIT0009],[@CIT0010] The close relationship is due to common etiologies (i.e., aging, smoking), increased systemic inflammation, hypoxemia, and increased pulmonary vascular resistance.[@CIT0010] The interplay between CVD and COPD increases the morbidity and mortality of each disorder. For instance, it has been shown that coronary artery calcification, a non-invasive marker for coronary artery disease is associated with increased mortality in COPD.[@CIT0011] However, it is debated if established CVD is an independent risk factor for COPD exacerbations.[@CIT0012],[@CIT0013] Regarding cardiovascular mortality, a strong association has been found with FVC,[@CIT0014] FEV~1~,[@CIT0015]--[@CIT0017] and the rate of lung function decline[@CIT0018] in population-based studies, suggesting that cardiovascular morbidity may be a relevant factor when investigating the relationship between lung function and mortality. Finally, COPD exacerbations pose an increased risk for cardiovascular events.[@CIT0019],[@CIT0020]

Given the contrasting findings illustrated above, and the need to risk stratify COPD patients with comorbid CVD, we aimed to examine the prognostic value of the spirometric indices by analyzing the data of the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial.

Patients and Methods {#S0002}
====================

Study Design and Participants {#S0002-S2001}
-----------------------------

The SUMMIT was a multicenter, randomized, double-blind, parallel-group, placebo-controlled trial assessing the effect of once-daily treatment with fluticasone furoate/vilanterol (100/25 μg), fluticasone furoate (100 μg), vilanterol (25 μg), or matched placebo on mortality in patients with moderate COPD; i.e., FEV~1~ between 50% and 70% of predicted value, and an increased cardiovascular risk.[@CIT0021] For patients ≥40 years of age, this was defined as any one of the following: established coronary artery disease, established peripheral vascular disease, previous stroke, previous myocardial infarction, or diabetes mellitus with target organ disease. In addition, for patients ≥60 years of age, any one of the criteria applicable for patients ≥40 years of age or two of the following: being treated for hypercholesterolemia, being treated for hypertension, being treated for diabetes mellitus, or being treated for peripheral vascular disease.[@CIT0021] The event-driven study included 16,485 participants and lasted until at least 1000 deaths were recorded. There was no difference between the four treatment arms for the primary outcome of all-cause mortality.[@CIT0022]

In this post hoc analysis of the SUMMIT study population, we hypothesized that FVC may be a better predictor of overall mortality and major cardiovascular events than FEV~1~ and FEV~1~/FVC, whereas FEV~1~ and FEV~1~/FVC would be stronger predictors of COPD exacerbations than FVC.

Major cardiovascular events included cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. We analyzed moderate to severe and severe exacerbations separately. A moderate COPD exacerbation was defined as an exacerbation treated with antibiotics and/or systemic corticosteroids whereas a severe COPD exacerbation required hospitalization.

All participants in the current analysis provided written, informed consent for trial participation. The study was conducted at 1373 sites in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by local ethics committees ([[Supplement 1](http://www.dovepress.com/get_supplementary_file.php?f=242809.doc)]{.ul}). Trial registration number: NCT01313676.

Lung Function Measurements {#S0002-S2002}
--------------------------

Post-bronchodilator spirometry has been performed according to the European Respiratory Society/American Thoracic Society guidelines.[@CIT0023] Prior to the spirometry long-acting β-agonists and inhaled corticosteroids were withheld for 48 hours, long-acting muscarinic antagonists were withheld for 1 week. Patients with systemic steroid use within 30 days were not included. Lung function measurements at screening were repeated after a 4--10 days run-in period at the baseline visit.

Statistical Analyses {#S0002-S2003}
--------------------

For each measure (percent predicted FEV~1~, percent predicted FVC and FEV~1~/FVC ratio), participants were allocated into lung function quintiles ([Table 1](#T0001){ref-type="table"}). The number of volunteers allocated in each quintile was compared between the screening and baseline visit.Table 1Association Between Lung Function Indices and Time to Mortality, Cardiovascular Events, Moderate and Severe Exacerbations, and Severe ExacerbationsTime to Death Risk Reduction vs. Q1Time to First Major Cardiovascular Event \
Risk Reduction vs. Q1Time to First Moderate/Severe Exacerbation Risk Reduction vs. Q1Time to First Severe Exacerbation Risk Reduction vs. Q1FEV~1~% PredictedQ1 \<53.5%Q2 53.5 to 57.5%**20% (4 to 34%)**5% (−20 to 25%)**11% (3 to 19%)**10% (−5 to 23%)Q3 57.5 to 61.6%**28% (13 to 40%)**15% (−8 to 33%)**15% (7 to 22%)25% (12 to 37%)**Q4 61.6 to 65.8**23% (7 to 36%)**9% (−15 to 28%)**23% (16 to 30%)37% (25 to 47%)**Q5 ≥65.8%**30% (15 to 42%)**7% (−18 to 26%)**27% (20 to 33%)40% (28 to 49%)**FVC % PredictedQ1 \<67.4%Q2 67.4 to 73.6%14% (−4 to 29%)16% (−7 to 34%)2% (−8 to 10%)4% (−15 to 20%)Q3 73.6 to 79.5%11% (−8 to 27%)−4% (−30 to 17%)−4% (−14 to 5%)0% (−20 to 17%)Q4 79.5 to 87.6%14% (−4 to 29%)11% (−13 to 29%)−6% (−17 to 3%)−13% (−34 to 6%)Q5 ≥87.6%**21% (4 to 35%)**21% (−1 to 38%)**−22% (−34 to −11%)−28% (−52 to −8%)**FEV~1~/FVCQ1 \<0.51Q2 0.51 to 0.570% (−21 to 16%)−7% (−36 to 16%)**18% (11 to 25%)22% (9 to 33%)**Q3 0.57 to 0.627% (−12 to 24%)−8% (−38 to 15%)**28% (22 to 35%)39% (28 to 49%)**Q4 0.62 to 0.6610% (−10 to 26%)−12% (−43 to 12%)**29% (22 to 35%)41% (29 to 50%)**Q5 ≥0.66−5% (−28 to 14%)−18% (−50 to 8%)**36% (30 to 42%)48% (37 to 57%)**[^1][^2]

For primary analyses, lung function data at screening were analyzed. Cox proportional hazards models were applied, adjusted for age, sex, ethnicity, body mass index (BMI), smoking status, previous COPD exacerbations, cardiovascular entry criteria, ischemic and vascular disease indicators, treatment, and modified Medical Research Council (mMRC) dyspnea score. For each outcome, the lowest quintile (Q1) for each lung function measure was used as the reference. Data are expressed as median (95% confidence interval).

Results {#S0003}
=======

Distribution of Lung Function Data {#S0003-S2001}
----------------------------------

In total, data of 16,485 participants of the intent-to-treat analysis were investigated. Lung function data both at screening and baseline were grouped into quintiles. When comparing the number of patients allocated to each quintile at screening and baseline (at randomization), respectively, only 44%, 54%, and 54% of participants were grouped in the same FEV~1~, FVC, and FEV~1~/FVC quintiles, illustrating the variability in these spirometric indices ([Table 2](#T0002){ref-type="table"}).Table 2Distribution of Participants in Lung Function Quintiles at Screening and BaselineFEV~1~ScreeningQ1: \<53.5% (N=3296)Q2: ≥53.5 to \<57.5% (N=3297)Q3: ≥57.5 to \<61.6% (N=3297)Q4: ≥61.6 to \<65.6% (N=3297)Q5: ≥65.6% (N=3296)BASELINEQ1: \<52.3% (N=3296)184485835017865Q2: ≥52.3 to \<56.7% (N=3297)9411167741311137Q3: ≥56.7 to \<61.1% (N=3297)3198081109732329Q4: ≥61.1 to \<66.0% (N=3297)1193087431235892Q5: ≥66.0% (N=3297)731563548411873**FVCQ1: \<67.4% (N=3296)Q2: ≥67.4 to \<73.6% (N=3297)Q3: ≥73.6 to \<79.5% (N=3297)Q4: ≥79.5 to \<87.6% (N=3297)Q5: ≥87.6% (N=3297)**Q1: \<52.3% (N=3296)217370226411344Q2: ≥65.9 to \<72.6% (N=3297)798141273926682Q3: ≥72.6 to \<78.8% (N=3297)2248561357690170Q4: ≥78.8 to \<87.2% (N=3297)682727731548635Q5: ≥87.2% (N=3297)33551646802365**FEV~1~/FVCQ1: \<0.51 (N=3296)Q2: ≥0.51 to \<0.57 (N=3297)Q3: ≥0.57 to \<0.62 (N=3297)Q4: ≥0.62 to \<0.66 (N=3296)Q5: ≥0.66 (N=3297)**Q1: \<0.51 (N=3296)24806101223733Q2: ≥0.51 to \<0.57 (N=3297)609166872019690Q3: ≥0.57 to \<0.62 (N=3297)1127181428757269Q4: ≥0.62 to \<0.66 (N=3296)521817161407955Q5: ≥0.66 (N=3297)331032968881935[^3]

FEV~1~, FVC, and FEV~1~/FVC as Predictors for All-Cause Mortality, Cardiovascular Events, and COPD Exacerbations {#S0003-S2002}
----------------------------------------------------------------------------------------------------------------

Compared with patients with the lowest FEV~1~ (Q1, \<53.5% predicted), each of the higher quintiles was associated with better survival, ranging from a 20% lower risk in Q2 to a 30% lower risk in Q5 ([Table 1](#T0001){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). Although there was a trend for decreasing mortality along the increasing quintiles of FEV~1~/FVC (7.8%, 6.7%, 5.9%, 5.4%, and 5.9%, from Q1 to Q5), this did not reach the level of significance. In contrast, for FVC only mortality in quintile 5 (FVC≥87.6% predicted) differed significantly from that of quintile 1 (FVC\<67.4% predicted). No lung function indices were predictive of a major cardiovascular event.Figure 1Kaplan--Meier plot showing unadjusted relationship between FEV~1~% predicted at screening and all-cause mortality.**Abbreviations:** FEV~1~, forced expiratory volume in one second; N, number of patients.

Compared with quintile 1, higher FEV~1~ and FEV~1~/FVC quintiles were all associated with a reduction of risk of moderate-to-severe and severe exacerbations ([Table 1](#T0001){ref-type="table"}). Unexpectedly, quintile 5 of FVC showed an increased risk of a moderate-to-severe and severe exacerbation compared to quintile 1. Despite analyzing FEV~1~ within a narrow range (50--70%), there was a strong association between FEV~1~ and exacerbation risk, with the lowest FEV~1~ quintile having a 27% higher risk of moderate/severe exacerbations compared with the highest FEV~1~ quintile (≥65.8%), and a 40% increase for severe exacerbations.

Discussion {#S0004}
==========

Analyzing the results of the SUMMIT trial, we found that FEV~1~ was a better predictor for mortality and exacerbation risk than FVC, while neither of them was associated with the risk for major cardiovascular events. The clearer relationship between mortality and FEV~1~ than with FVC suggests that airflow limitation, rather than lung volume, predicts mortality in patients with COPD and heightened cardiovascular risk.

Previous general population studies highlighted the predictive role of FVC versus FEV~1~.[@CIT0006],[@CIT0014] There are possible explanations for the discrepancies. First, the current study included only patients with an obstructive lung function pattern.[@CIT0021] A restrictive pattern may also be common in the general population and associated with poverty[@CIT0007] and morbid obesity, which may both lead to increased mortality.[@CIT0024] Although our analysis was adjusted for BMI, socioeconomic data were unavailable and several other variables, such as very severe heart failure (which may lead to reduced FVC), were not included, which may have influenced our findings. While inclusion into SUMMIT was not restricted by FVC as it was for FEV~1~, we only included patients with moderate COPD, which imposed some restrictions on FVC indirectly. In this sense, the previously seen association between reduced lung volumes and cardiovascular outcomes may have been driven by subjects with very low FVC.[@CIT0014]

We found a steep gradient between FEV~1~ quintiles and exacerbation risk. As the FEV~1~ cut-off value generally applied for separating moderate from severe COPD is quite arbitrary, our findings add to the increasing perception that, for usual clinical care, these arbitrary FEV~1~ cut-off values hold little clinical value.

Our article also highlights the obscurity of lung function values from a single spirometry. Only approximately half of the participants allocated to different lung function quintiles at screening were grouped in the same quintile at baseline. Indeed, approximately 1% of patients changed from the lowest to highest quintiles or vice versa. This can be likely explained by the methodological variability of lung function measurements and physiological variability of the airway caliber.

Our analysis has limitations. Only patients with moderate COPD were included and a wider lung function range would likely have provided more robust data. Lung function aside, hypoxia, hypercapnia, BMI, dyspnea, and exercise capacity are also strong predictors of mortality in COPD.[@CIT0001] Although our analyses were adjusted for BMI and mMRC dyspnea score, blood gas values and exercise capacity test were not available in SUMMIT. However, patients on long-term oxygen were excluded, as were those with very severe heart failure, severe renal failure, or whose life expectancy from diseases other than vascular disease and COPD was under 3 years. We therefore do not believe that our findings are the result of confounding by these other risk factors.

Confirming previous findings, lower FEV~1~ and FEV~1~/FVC were associated with higher risk for COPD exacerbations.[@CIT0013],[@CIT0025],[@CIT0026] Increased disease severity is associated with heightened airway and systemic inflammation.[@CIT0027] The ECLIPSE study highlighted the potential role of persistent systemic inflammation leading to frequent exacerbations.[@CIT0028] However, analyzing the SUMMIT data, the levels of systemic inflammatory biomarkers did not relate to the frequency of flare-ups.[@CIT0029] Interestingly we found that the highest FVC quintile was associated with an increased exacerbation risk. This, together with the gradually increased risk for exacerbation with FEV~1~ decline suggest that more severe emphysema may be related to higher number of exacerbations. This is in line with the ECLIPSE study﻿;[@CIT0025] however, no computed tomography was performed in the SUMMIT trial. Our results are similar to the findings of the TIOSPIR study showing that larger FVC was associated with increased exacerbation risk.[@CIT0012]

Conclusion {#S0005}
==========

In conclusion, we found strong relationships between FEV~1~ and exacerbation rate and all-cause mortality, but not with major cardiovascular events, in SUMMIT. These were stronger than for FVC and stronger than we anticipated for patients with moderate COPD and a limited FEV~1~ range.

AB and JV are supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC). Editorial support (in the form of editorial alignment with journal guidance) was provided by Kirsty Millar, MSc, of Gardiner-Caldwell Communications (Macclesfield, UK), and was funded by GlaxoSmithKline plc.

Abbreviations {#S0006}
=============

BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; SUMMIT, Study to Understand Mortality and Morbidity.

Data Sharing {#S0007}
============

The authors confirm that they intend to share individual deidentified participant data, including demographics, comorbidities, mortality, lung function, and treatment. In addition, other study-related documents will be made available, including raw dataset, analysis ready dataset, reporting and analysis plan, clinical study report, case report forms, and protocol.

It is GSK policy to provide access to patient-level data within 6 months of publishing the results of the primary endpoints of the study. Researchers can enquire about the availability of data from GSK clinical studies that are not listed on [[www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)]{.ul} before they submit a research proposal. To access data for other types of GSK sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via [[www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)]{.ul}.

Disclosure {#S0008}
==========

AB reports fees from AstraZeneca, Chiesi, and Sandoz. PL reports grants from AstraZeneca and GlaxoSmithKline and fees from Boehringer Ingelheim, AstraZeneca, Novartis, and GlaxoSmithKline. JAA, CC, and JCY are employees of and hold stock in GlaxoSmithKline plc. PMAC reports fees from GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca. BRC reports fees from GlaxoSmithKline. NJC and IJD are employed by Veramed Ltd, a Contract Research Organization undertaking contracted statistical analyses of studies funded by GlaxoSmithKline plc. FJM reports grants, personal fees, non-financial support from AstraZeneca, personal fees, non-financial support from Boehringer Ingelheim, non-financial support from Proterrix Bio, personal fees from CME Outfitters, personal fees from Gala, Asthma DSMB from Genentech/Roche, grants, personal fees, non-financial support from GlaxoSmithKline, personal fees from INOVA Fairfox, personal fees from Miller Communications, personal fees from National Association for Continuing Education, personal fees from Novartis, personal fees from Pearl, personal fees from PeerView, personal fees from Physicians Education Resource, personal fees from Prime Education, personal fees from Sunovion, personal fees from Teva, personal fees, non-financial support from UpToDate, personal fees from WebMD/Medscape, during the conduct of the study; personal fees from Gentech, and is involved with COPD CME for UpToDate. DEN reports fees from GlaxoSmithKline. JV reports fees from GSK, AstraZeneca, Boehringer-Ingelheim, Chiesi, and Novartis. The authors report no other conflicts of interest in this work.

[^1]: **Notes:** Results are from Cox Proportional Hazard models and are presented as risk reduction compared with Q1 quintile groups (with 95% confidence intervals). These are calculated as (1--hazard ratio) × 100. Negative % reductions indicate increase in risk, i.e., hazard ratio \>1. Nominally significant differences are presented in bold (p\<0.05, no adjustment for multiplicity).

[^2]: **Abbreviations:** FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.

[^3]: **Abbreviations:** FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.
